NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
51862-0460-01 | 51862-0460 | Cyclosporine | Cyclosporine | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Jul 18, 2016 | In Use | |
68382-0914-16 | 68382-0914 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2020 | In Use | |
64380-0129-02 | 64380-0129 | Cyclosporine | Cyclosporine | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Aug 16, 2022 | In Use | |
58181-3042-05 | 58181-3042 | Lomustine | Gleostine | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrosourea | Oral | Aug 18, 2014 | In Use | |
30698-0121-05 | 30698-0121 | Dolasetron mesylate | Anzemet | 100.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 11, 1997 | May 24, 2021 | In Use |
50242-0210-60 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Jul 1, 2021 | In Use | |
62332-0566-30 | 62332-0566 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jul 9, 2021 | In Use | |
00378-5262-14 | 00378-5262 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jun 29, 2016 | Feb 28, 2018 | No Longer Used |
00591-2897-49 | 00591-2897 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Sep 22, 2016 | Apr 30, 2019 | No Longer Used |
40051-0606-11 | 40051-0606 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 1, 2016 | In Use | |
00310-4513-60 | 00310-4513 | Acalabrutinib | CALQUENCE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Feb 19, 2025 | In Use | |
59651-0531-03 | 59651-0531 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jun 22, 2022 | In Use | |
54868-5350-00 | 54868-5350 | Temozolomide | Temodar | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct 7, 2005 | In Use | |
72482-0100-12 | 72482-0100 | Pacritinib | Vonjo | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | JAK2, FLT3 | Oral | Feb 28, 2022 | In Use | |
68001-0620-54 | 68001-0620 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jan 10, 2025 | In Use | |
00185-0933-86 | 00185-0933 | Cyclosporine | Cyclosporine | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Nov 21, 2015 | Feb 28, 2020 | No Longer Used |
00078-0241-15 | 00078-0241 | Cyclosporine | Sandimmune | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Mar 2, 1990 | In Use | |
70771-1522-03 | 70771-1522 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2020 | In Use | |
65162-0794-03 | 65162-0794 | Imatinib | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 8, 2019 | In Use | |
00074-0576-34 | 00074-0576 | Venetoclax | Venclexta | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BCL-2 | Oral | Nov 21, 2018 | In Use | |
60505-2900-01 | 60505-2900 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 5, 2016 | In Use | |
46708-0566-90 | 46708-0566 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jul 9, 2021 | In Use | |
00310-0668-60 | 00310-0668 | Olaparib | Lynparza | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Aug 17, 2017 | In Use | |
00143-9606-01 | 00143-9606 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jun 8, 2020 | In Use | |
69656-0103-61 | 69656-0103 | Niraparib | Zejula | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Jul 1, 2020 | Aug 31, 2024 | No Longer Used |
Found 11765 results — Export these results